File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial

TitleDose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial
Authors
Yuen, RMFElkashab, MChen, CYCoffin, CFung, SGreenbloom, SJang, JWJeng, RWJKim, DJKim, YJKim, WLee, KSLim, YSRamji, AIyer, RMacfarlane, CJackson, KLocarnini, SAfdhal, NChan, H
Issue Date2018
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress 2018, Paris, France, 11-15 April 2018. In Journal of Hepatology, 2018, v. 68 n. Suppl. 1, p. S509-S510 How to Cite?
DOI: http://dx.doi.org/10.1016/S0168-8278(18)31267-4
DescriptionPoster Presentation - no. FRI-327
Persistent Identifierhttp://hdl.handle.net/10722/264590
ISSN
0168-8278
2021 Impact Factor: 30.083
2020 SCImago Journal Rankings: 7.112
ISI Accession Number ID
WOS:000461068602234

 

DC FieldValueLanguage
dc.contributor.authorYuen, RMF-
dc.contributor.authorElkashab, M-
dc.contributor.authorChen, CY-
dc.contributor.authorCoffin, C-
dc.contributor.authorFung, S-
dc.contributor.authorGreenbloom, S-
dc.contributor.authorJang, JW-
dc.contributor.authorJeng, RWJ-
dc.contributor.authorKim, DJ-
dc.contributor.authorKim, YJ-
dc.contributor.authorKim, W-
dc.contributor.authorLee, KS-
dc.contributor.authorLim, YS-
dc.contributor.authorRamji, A-
dc.contributor.authorIyer, R-
dc.contributor.authorMacfarlane, C-
dc.contributor.authorJackson, K-
dc.contributor.authorLocarnini, S-
dc.contributor.authorAfdhal, N-
dc.contributor.authorChan, H-
dc.date.accessioned2018-10-22T07:57:28Z-
dc.date.available2018-10-22T07:57:28Z-
dc.date.issued2018-
dc.identifier.citationThe International Liver Congress 2018, Paris, France, 11-15 April 2018. In Journal of Hepatology, 2018, v. 68 n. Suppl. 1, p. S509-S510-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/264590-
dc.descriptionPoster Presentation - no. FRI-327-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.relation.ispartofThe International Liver Congress 2018-
dc.titleDose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial-
dc.typeConference_Paper-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.doi10.1016/S0168-8278(18)31267-4-
dc.identifier.hkuros293851-
dc.identifier.volume68-
dc.identifier.issueSuppl. 1-
dc.identifier.spageS509-
dc.identifier.epageS510-
dc.identifier.isiWOS:000461068602234-
dc.publisher.placeNetherlands-
dc.identifier.issnl0168-8278-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats